A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials

Multiple interventions are available for the treatment of actinic keratosis (AK) showing high efficacy in pivotal trials. However, data from post-marketing surveillance studies have received little attention until now. Here, we systematically investigate interventions for AK from post-marketing surveillance trials as a proxy for real-world efficacy and tolerability. A systematic literature search was conducted in Medline, Embase, and CENTRAL. Pertinent trial registers were hand-searched until 25 March 2020. Results were pooled using a random-effects model to calculate pooled proportions and relative risks (RR) or were described qualitatively. Eleven records with a total sample size of n = 4109 were included. Three of the studies had an active-controlled design, while seven were single-armed. Participant complete clearance ranged from 23.1% for diclofenac sodium 3% gel to 88.9% for ingenol mebutate 0.05% gel. The lesion-specific clearance rate for photodynamic therapy (PDT) was 74% (95% confidence interval (CI) 56–87%). The recurrence rate was significantly higher for diclofenac sodium 3% in comparison to imiquimod 5% cream (RR 1.10, 95% CI 1.02–1.1.8) and ranged from 10.6% for ingenol mebutate 0.015% gel to 23.5% for PDT. Few patients discontinued the trials due to adverse events. The results from the majority of the post-marketing surveillance studies deviated from those of pivotal trials.

[1]  C. Berking,et al.  Cash is king: the balance of costs and effectiveness of treatments for actinic keratosis , 2020, The British journal of dermatology.

[2]  C. Berking,et al.  S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of‐care indicators , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[3]  N. Kelleners-Smeets,et al.  A trial‐based cost‐effectiveness analysis of topical 5‐fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands , 2020, The British journal of dermatology.

[4]  H. Kerl,et al.  Long‐term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[6]  E. Bierhoff,et al.  Somatic mutations in kinetochore gene KNSTRN are associated with basal proliferating actinic keratoses and cutaneous squamous cell carcinoma , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  P. Steijlen,et al.  Randomized Trial of Four Treatment Approaches for Actinic Keratosis , 2019, The New England journal of medicine.

[8]  J. Denison,et al.  The Evidence Project risk of bias tool: assessing study rigor for both randomized and non-randomized intervention studies , 2019, Systematic Reviews.

[9]  H. Kurzen,et al.  Photodynamic therapy with a 5‐ALA patch does not increase the risk of conversion of actinic keratoses into squamous cell carcinoma , 2018, Experimental dermatology.

[10]  E. Nagore,et al.  A randomized intraindividual comparative study of methyl‐5‐aminolaevulinate vs. 5‐aminolaevulinic acid nanoemulsion (BF‐200 ALA) in photodynamic therapy for actinic keratosis of the face and scalp , 2018, The British journal of dermatology.

[11]  S. Jo,et al.  A multicentre, open, investigator‐initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0·015% on the face and scalp, and 0·05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT) , 2018, The British journal of dermatology.

[12]  T. Gambichler,et al.  Cutaneous squamous cell carcinomas are associated with basal proliferating actinic keratoses , 2018, The British journal of dermatology.

[13]  T. Skov,et al.  Phase IV head‐to‐head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp , 2017, The British journal of dermatology.

[14]  U. Reinhold,et al.  Low‐dose 5‐fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms – results of a non‐interventional study , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  J. McGregor,et al.  British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017 , 2017, The British journal of dermatology.

[16]  C. Berking,et al.  A randomized, double‐blind, phase III, multicentre study to evaluate the safety and efficacy of BF‐200 ALA (Ameluz®) vs. placebo in the field‐directed treatment of mild‐to‐moderate actinic keratosis with photodynamic therapy (PDT) when using the BF‐RhodoLED® lamp , 2016, The British journal of dermatology.

[17]  T. Dirschka,et al.  Efficacy of low‐dose 5‐fluorouracil/salicylic acid in actinic keratoses in relation to treatment duration , 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[18]  M. Paquet,et al.  Network meta‐analysis of the outcome ‘participant complete clearance’ in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow‐up on a Cochrane review , 2013, The British journal of dermatology.

[19]  V. Kiri A Pathway to Improved Prospective Observational Post-Authorization Safety Studies , 2012, Drug Safety.

[20]  Neil Swanson,et al.  Ingenol mebutate gel for actinic keratosis. , 2012, The New England journal of medicine.

[21]  Ş. Aktan,et al.  Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses , 2011, Clinical and experimental dermatology.

[22]  C. Garbe,et al.  Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[23]  D. Rigel,et al.  Long-term Follow up of Diclofenac Sodium 3% in 2.5% Hyaluronic Acid Gel for Actinic Keratosis: One-year Evaluation. , 2009, The Journal of clinical and aesthetic dermatology.

[24]  D. Rigel,et al.  Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. , 2008, Journal of drugs in dermatology : JDD.

[25]  E. Çalışkan,et al.  Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis , 2008, The Journal of dermatological treatment.

[26]  S. Glasser,et al.  Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self‐Reporting Systems , 2007, Journal of clinical pharmacology.

[27]  E. Tschen,et al.  Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12‐month follow up , 2006, The British journal of dermatology.

[28]  N. Swanson,et al.  Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). , 2004, Journal of drugs in dermatology : JDD.

[29]  J. Hartung,et al.  A refined method for the meta‐analysis of controlled clinical trials with binary outcome , 2001, Statistics in medicine.

[30]  M D Rawlins,et al.  Review of company postmarketing surveillance studies. , 1992, BMJ.

[31]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[32]  S. Salasche,et al.  Epidemiology of actinic keratoses and squamous cell carcinoma. , 2000, Journal of the American Academy of Dermatology.

[33]  R. Moy Clinical presentation of actinic keratoses and squamous cell carcinoma. , 2000, Journal of the American Academy of Dermatology.